Orange, there's a lot left to be discovered about Kalydeco as a mono therapy. So far, it's only been tested in DDf508 and G551D. That's why many people are trying the drug, even if they don't have G551D. It will be exciting to see what people report after trying the med. And some insurances are paying for it. The amount of CFTR that a gene can create can be influenced by a lot of things - modifier genes, exercise, the food we eat. So Kalydeco may have different impacts on different people....